Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-owned MagForce publishes study results of Nano-Cancer® therapy in leading medical journal

Abstract:
* Detailed information shared with international medical and scientific community
* European product launch scheduled for first quarter of 2011
* Further strategic steps in planning

Nanostart-owned MagForce publishes study results of Nano-Cancer® therapy in leading medical journal

Berlin / Frankfurt | Posted on September 22nd, 2010

The internationally renowned Journal of Neuro-Oncology has published the results of a clinical study by MagForce Nanotechnologies AG (Frankfurt Stock Exchange:MF6), a majority-owned portfolio company of Nanostart AG, demonstrating the effectiveness of its Nano-Cancer® therapy in the treatment of patients with recurrent glioblastoma. These clinical trials served as the basis for EU regulatory approval, received in June 2010, of this revolutionary new approach to treating solid tumors.

The Journal of Neuro-Oncology is an international multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research.

With this publication in the Journal of Neuro-Oncology, the detailed results of clinical trials demonstrating the effectiveness of Nano-Cancer® therapy have now for the first time been shared with the international scientific and medical community.

According to statements made by Dr. Peter Heinrich, CEO of MagForce Nanotechnologies, the company is currently planning further strategic steps. Product introduction, starting with the German market, is schedule to commence in the first quarter of 2011. Sale and marketing teams for product commercialization, as well as the needed infrastructure, are currently being put in place. In addition, other clinical trials will be initiated, and the company will be structured to optimally serve the international market.

The full journal article, entitled "Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme," may be found at www.springerlink.com/content/u27ll42612302123/ or www.ncbi.nlm.nih.gov/pubmed/20845061

The study reported on the treatment of 59 cancer patients suffering from recurrent glioblastoma, a particularly aggressive form of brain tumor. Using Nano-Cancer® therapy in conjunction with radiotherapy, the median survival time of the patient group was 13.4 months, compared to 6.2 months using existing conventional therapies in a control study. The median survival time was thus more than doubled, a significant increase. In addition, the new therapy offers the advantage of minimal side effects and reduced patient discomfort compared to existing therapeutic alternatives.

####

For more information, please click here

Contacts:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122

Copyright © Nanostart

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Leti Presents Advances in Propagation Modeling and Antenna Design for mmWave Spectrum: Paper Is One of 15 that Leti Presented at European Conference on Antennas and Propagation March 19-24 March 23rd, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Nanomedicine

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

Announcements

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Nanobiotechnology

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project